Malignant Neoplasm of Gastrointestinal Tract Clinical Trial
Official title:
Impact of Mechanism Based Acupuncture Intervention to Improve Weight Loss in GI Cancer Patients With Cachexia
Verified date | January 2019 |
Source | University of Florida |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with cancer often experience appetite loss and weight loss unintentionally. Rapid weight loss negatively impact on physical functioning, quality of life, and overall survival. Patients will be randomly assigned into two groups. An intervention with acupuncture may slow down or stop the progression of cancer-related anorexia and weight loss.
Status | Completed |
Enrollment | 45 |
Est. completion date | May 2016 |
Est. primary completion date | May 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - 21 year or older - medical diagnosis of gastrointestinal cancer (for example, gastric, biliary, or colorectal) - experienced weight loss of at least 5% over the last 6 months - ability to communicate in English - ability to follow the research protocol Exclusion Criteria: - plan to have surgical procedures at the time of recruitment - receive radiation therapy alone or in addition to chemotherapy during the study period - undergo surgery during the study or in the months prior to the study - no plan to have chemotherapy after the surgery - any comorbidities that may affect the interpretation of study findings - open burn sites or infected wounds - esophageal cancer or pancreatic cancer - life expectancy of less than 6 months as assessed by attending physician |
Country | Name | City | State |
---|---|---|---|
United States | University of Florida Clinical Research Center (CRC) | Gainesville | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Florida |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Quality of life between two arms | Survey format includes the 27 items (5 points scale: 0 means 'not at all' and 4 means 'very much") . | up to 8 weeks | |
Other | biomarkers | Small amounts of blood will be drawn. | weeks 1, 4 and 8 (three measurements) | |
Other | symptom experience | Survey format: 13 areas related to the symptom experience and patient's concerns will be assessed (4 points scale; 0 means 'not at all' and 3 means 'very much'). | up to 8 weeks | |
Primary | Percentage weight change over 8 weeks between two arms | Weight will be measured each visit (pounds). | up to 8 weeks | |
Secondary | Appetite change between two arms | Three different short survey forms will be used to measure appetite change. Visual analogue scale (0 indicates no appetite and 10 is the best appetite). Simplified Nutritional Appetite Questionnaire score (min-max: 4-20 and the higher the better appetite) Patient Generated Subjective Global Assessment: 0-1, no intervention is needed. 9 or higher score indicates critical intervention. | up to 8 weeks | |
Secondary | physical functioning | survey form (min-max: 0-100, increment by 10%- 100% indicates full functioning). | up to 8 weeks | |
Secondary | body composition | Small, non-invasive device (bioelectrical impedance analysis) like a miniature version of EKG will measure changes in body composition (numeric scale). | up to 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01639911 -
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
|
Phase 1 |